Log In
BCIQ
Print this Print this
 

ulocuplumab (BMS-936564) (formerly MDX-1338)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman IgG4 mAb against CXC chemokine receptor 4 (CXCR4; NPY3R)
Molecular Target CXC chemokine receptor 4 (CXCR4) (NPY3R)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat relapsed or refractory acute myelogenous leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today